Joseph Schérer

Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir

John D. Baxter, Jonathan Schapiro, Charles A. Boucher et al. · Journal of Virology · 2006 · 132 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial

Mark Sulkowski, Tarik Asselah, Jacob Lalezari et al. · Hepatology · 2013 · 104 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

Mark S. Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki et al. · Hepatology · 2013 · 68 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Decrease of D2 receptors indicated by ¹²³I‐iodobenzamide single‐photon emission computed tomography relates to neurological deficit in treated Wilson's disease

W. H. Oertel, Klaus Tatsch, Johannes Schwarz et al. · Annals of Neurology · 1992 · 52 citations

Medicine, Neurology, Neuroscience +16

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

Dominique Larrey, Ansgar W. Lohse, Victor de Lédinghen et al. · Journal of Hepatology · 2012 · 39 citations

Pharmacy, Pharmacology, Pharmacotherapy +13